Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement Clinical Trial Optional)

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health is issuing a forecast for Urgent Competitive Revisions to existing grants and cooperative agreements. This initiative allows recipients of ongoing NIH awards to apply for funding to address unforeseen public health crises that emerged after their original application was submitted. Clinical trials are optional for these revisions. Eligible applicants must respond to a specific Urgent Guide Notice published by an Institute or Center to apply once the Notice of Funding Opportunity is officially issued. Applications will be routed directly to the NIH awarding component identified on the most recent parent award. The process is managed by the Division of Grants Policy within the Office of Policy for Extramural Research Administration.

General Info

NIH invites urgent grant revisions to address unexpected public health crises via expedited supplements.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

923120 - Administration of Public Health Programs

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedMar 4

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUSA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health

Office AddressUSA

Contacts

Division of Grants Policy (DGP) Office of Policy for Extramural Research Administration (OPERA

contact@example.gov

Full Description

Show more

The National Institutes of Health (NIH) intends to issue a Notice of Funding opportunity to allow applications for competitive revisions of ongoing grants to address specific public health crises that were unforeseen when the original application was submitted. Once this Notice of Funding Opportunity (NOFO) is approved and issued, applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the Notice of Award of the most recent parent award.

Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to the NOFO once it’s published.

Similar Contracts

Same NAICS industry code

NIH Operates Under a Continuing Resolution

Solicitation # NOT-OD-26-131

The National Institutes of Health is operating under the Continuing Appropriations and Extensions Act, 2027, which extends government operations through December 11, 2026, at the Fiscal Year 2026 enacted level. Under this resolution, the NIH is prohibited from implementing revisions to the Uniform Administrative Requirements for Federal Awards until the expiration date. Additionally, NIH Institutes and Centers maintain the discretion to issue non-competing research grant awards at levels lower than those listed on the most recent Notice of Award, with potential upward adjustments considered only after FY 2027 appropriations are enacted. All legislative mandates and fiscal policies from FY 2026 remain in effect, including the salary limitation set at Executive Level II of the Federal Pay Scale. The Ruth L. Kirschstein National Research Service Award stipend levels and tuition fees also remain consistent with previous notices. Institutions are expected to monitor their expenditures closely during this period to ensure financial stability until new appropriations are finalized.

National Institutes Of Health

POSTED

DEADLINE

Strengthening Collaboration Between Tuberculosis Control Programs and Affiliated Partners in the United States.The Centers for Disease Control and Prevention is offering funding to a single recipient to enhance collaboration and relationships between tuberculosis control programs, TB controllers, and various affiliated partners across the United States. This initiative builds upon previous efforts to strengthen ties with national TB control programs, federal agencies, academic institutions, businesses, and community or faith-based organizations. The primary goal of this effort is to support the CDC Division of Tuberculosis Elimination in its mission to prevent, control, and eventually eliminate tuberculosis to improve overall health and quality of life. This forecast is managed by the Department of Health and Human Services under the National Center for HIV, Viral Hepatitis, Hepatitis B, and STI, with Martha Boisseau serving as the point of contact.

Centers For Disease Control - Nchhstp

POSTED

DEADLINE

RHTP- Innovative Maternal Care

Solicitation # VDH-26-705-0387

The Virginia Department of Health is seeking projects under the Rural Health Transformation Program to expand maternal healthcare access and infrastructure in rural Virginia. This initiative focuses on improving outcomes through evidence-informed practices in prenatal, perinatal, postpartum, and maternal behavioral health services. Key objectives include strengthening care coordination, integrating substance use disorder services, leveraging telehealth and digital health technologies, and expanding community-based supports such as doulas and peer support. The program targets rural communities as defined by the Federal Office of Rural Health Policy, with a total anticipated funding pool of 11.6 million dollars and individual awards ranging from 50,000 to 1,000,000 dollars. The initial period of performance begins upon the execution of the subaward agreement and ends on September 30, 2027, with potential continuation funding available through September 30, 2030. Awards operate on a cost-reimbursement basis, requiring documentation that costs were paid prior to reimbursement. Applicants must be physically located in or provide direct services to rural Virginia and maintain an active SAM.gov registration. Evaluation is based on a 100-point scale considering quality, feasibility, and overall merit, with funding granted in rank order subject to programmatic priorities and organizational capacity. Applications must be submitted via the eVA portal by October 6, 2026, and include a cover page, executive summary, project narrative, and a detailed budget following 2 CFR Part 200 guidelines.

Virginia Department of Health

POSTED

DEADLINE

Notice of Opportunity to Participate in the Implementation Council for One Care

Solicitation # BD-27-1039-EHS01-ASHWA-133664

The Massachusetts Executive Office of Health and Human Services, through MassHealth, is soliciting diverse individuals and community-based organization representatives to serve on the Implementation Council for the One Care program. One Care is a coordinated health plan designed for eligible adults ages 21 to 64 that integrates Medicare and MassHealth benefits. The Council's primary purpose is to partner with MassHealth to improve program delivery by monitoring healthcare access, reviewing member experiences, and advising on strategies to strengthen the program. Members are expected to participate in virtual meetings held twice monthly for approximately two hours each. The initial term for Council members is two years with the possibility of an extension. Compensation includes a 75 dollar stipend for each Implementation Council meeting attended and 25 dollars per hour for approved engagement meetings or activities, such as in-person town halls. Applicants are evaluated based on the clarity and completeness of their application, their understanding of the Council's goals, and their relevant knowledge and experience. To avoid conflicts of interest, individuals with direct or indirect employment or contractual relationships with My Ombudsman or a One Care Plan are generally ineligible to serve. Interested parties must submit a completed application form by November 2, 2026, at 5:00 PM via the Mass.gov website, the COMMBUYS portal, or email. The application process requires personal information, narratives on community engagement, and geographic representation details. Final selections are made by the Assistant Secretary for MassHealth or a designee based on recommendations from an Evaluation Committee.

POSTED

DEADLINE

in about 1 month

Advancing Global Health

Solicitation # DFOP0017890

The Department of State Bureau of Global Health Security and Diplomacy is soliciting Statements of Interest under Annual Program Statement DFOP0017890 to advance the America First Global Health Strategy. This initiative seeks to save lives, strengthen health systems, and foster self-reliance through projects that complement bilateral Memoranda of Understanding with partner governments. The program utilizes a two-step application process, with an overall estimated funding pool of up to 4.5 billion dollars. Individual awards may range from 500,000 dollars to 250 million dollars over a performance period of up to five years. The program is implemented through various specific addenda targeting diverse health priorities and geographies. Key focus areas include the implementation of health MOUs in countries such as Nigeria, Uganda, Malawi, Mozambique, and Cote d'Ivoire, as well as thematic initiatives for the elimination of neglected tropical diseases, accelerating nutrition progress, rapid outbreak response, and innovative population-based surveillance. Specific funding allocations are outlined in these addenda, such as up to 200 million dollars for Nigeria and 180 million dollars for Mozambique. Applicants are evaluated based on three equally weighted criteria: the quality of the program idea, organizational capacity and previous grant record, and the ability to achieve objectives. While a Unique Entity Identifier and SAM.gov registration are not required for the initial Statement of Interest phase, they are mandatory for any organization moving into the full proposal phase. The Department emphasizes a transition toward government-led, sustainable, and accountable health systems, requiring recipients to adhere to strict federal regulations and reporting standards, including the use of Foreign Assistance Data Review elements for financial tracking.

Bureau Of Global Health Security And Diplomacy

POSTED

DEADLINE

RFI-2026-09-17-MAC

Solicitation # 234169

The Northern Health Authority, operating under the Province of British Columbia, has issued a sources-sought solicitation identified as RFI-2026-09-17-MAC with solicitation number 234169. This request for information is intended to identify potential providers capable of performing work within British Columbia. The solicitation was posted on September 17, 2026, and requires responses to be submitted by the deadline of October 6, 2026, at 11:30 PM. Further details and submission processes can be accessed through the BC Bid portal.

Northern Health Authority

POSTED

DEADLINE

Cancer Prevention and Control Programs for State, Territorial, and Tribal OrganizationsThe Centers for Disease Control and Prevention's Division of Cancer Prevention and Control is seeking eligible state, territorial, and tribal organizations to implement comprehensive cancer surveillance, prevention, and control strategies. The primary objective is to improve health outcomes through a coordinated approach that integrates clinical preventive services and cancer survivorship to reduce the overall cancer burden in targeted communities. Funding is allocated across three national programs. The National Breast and Cervical Cancer Early Detection Program provides screening and diagnostic services for low-income women without adequate insurance, with an optional component for evidence-based interventions. The National Comprehensive Cancer Control Program supports coalition-led efforts to execute jurisdiction-wide cancer plans, while the National Program of Cancer Registries focuses on the implementation of population-based central cancer registry programs.

Centers For Disease Control - Nccdphp

POSTED

DEADLINE

Native Public Health ResilienceThe Native Public Health Resilience initiative is a forecast opportunity issued by the Indian Health Service under the Department of Health and Human Services. This program is specifically designed to provide funding to Tribes and Tribal Organizations to support the delivery of Essential Public Health Services. The opportunity is managed by the Division of Grants Management, with a posted date of September 10, 2026. Interested parties can coordinate through the provided point of contact or access further details via the official grants.gov portal.

Indian Health Service

POSTED

DEADLINE

Solicitation # 376

The Council of State and Territorial Epidemiologists (CSTE), in partnership with the Centers for Disease Control and Prevention (CDC), is offering funding to non-federal public health entities, including state, Tribal, local, and territorial agencies, academic institutions, and nonprofit organizations. The program focuses on promoting One Health collaborations and community education regarding influenza and other zoonotic diseases specifically targeting youth in agriculture. The primary objectives are to develop stakeholder relationships, implement a multisectoral One Health approach to disease prevention, evaluate the impact of public health interventions, and motivate positive behavior changes to prevent the spread of zoonotic infections. Selected awardees will receive a firm-fixed subaward of up to 50,000 dollars per site. The project period runs from October 23, 2026, to July 31, 2027, with final deliverables and invoices due by August 31, 2027. Key deliverables include the formation of a project coordination team, the delivery and evaluation of educational content, and the submission of four written progress reports. Applications are evaluated based on the quality of the proposal, the applicant's understanding of the public health issue, the work plan and budget, and the ability to leverage existing resources. All awards are subject to federal cost principles under 2 CFR 200 and require certifications regarding drug-free workplaces, anti-discrimination compliance, and the prohibition of federal funds for lobbying.

Council of State and Territorial Epidemiologists

POSTED

DEADLINE

Bid No. 27-040 2027 Shannon Community Safety Initiative Grant Program

Solicitation # BD-27-1167-PUR02-PUR01-133232

The 2027 Shannon Community Safety Initiative (CSI) Grant Program, identified as Bid No. 27-040, is a competitive grant opportunity administered by the Springfield Police Department through the Office of Administration and Finance. Funded by the Executive Office of Public Safety and Security (EOPSS), the program utilizes the Office of Juvenile Justice and Delinquency Prevention Comprehensive Gang Model to combat gang and youth violence. The initiative supports regional, multi-disciplinary approaches focusing on coordinated prevention, intervention, law enforcement, prosecution, and reintegration. The anticipated funding cycle runs from approximately January 1, 2027, through December 31, 2027, with the actual start date dependent on the state contract. The City of Springfield is applying for a maximum award of $1,000,000.00 from EOPSS and intends to make 67% of the total granted funds available to Shannon Partners, with community-based program agencies eligible to apply for up to $80,000.00. Preference is given to proposals that target geographical areas with high levels of youth violence, gang activity, and substance abuse, demonstrate a commitment to neighborhood-based strategies, and outline comprehensive plans with multidisciplinary partners. Additionally, city or quasi-city based organizations are encouraged to provide a 25% match from public or private sources. Proposals must be submitted to the Office of Procurement by 2:00 PM on October 5, 2026.

PUR02 - Procurement

POSTED

DEADLINE

Limited Competition: John Lewis NIMHD Research Endowment Program (S21 Clinical Trial Not Allowed)The John Lewis NIMHD Research Endowment Program, administered by the National Institutes of Health under the Department of Health and Human Services, is designed to enhance research infrastructure and training capacity at eligible institutions of higher education to support health disparities research. The program focuses on four strategic objectives: upgrading physical infrastructure and equipment, developing technical expertise, expanding relevant academic science programs, and recruiting high-level researchers for faculty positions. It is important to note that this program provides institutional support and does not directly fund specific research projects. This opportunity is a forecast for a limited competition, meaning only eligible organizations will be invited to apply. Applications will undergo a standard NIH peer-review process, and funding will be awarded based on the merit of the proposal. Clinical trials are not allowed under this specific program.

National Institutes Of Health

POSTED

DEADLINE

Preadmission Screening and Resident Review

Solicitation # AHCA RFP 001-26/27

The State of Florida Agency for Health Care Administration is soliciting proposals under RFP 001-26/27 to contract with a vendor for the maintenance and management of the Preadmission Screening and Resident Review process. The scope of work includes managing Level I screenings and Level II evaluations, identifying specialized rehabilitative services, and developing and maintaining a web-based data system to improve administrative efficiency. The selected vendor will also provide education, training, and technical assistance to agency staff and involved entities. The agency estimates the total contract value at 9,773,720.00 dollars, with an annual estimated amount of 2,443,430.00 dollars. The contract follows a fixed-price unit cost model covering a one-time implementation period, four years of initial operations, and up to four renewal years. Key deliverables include monthly, quarterly, and annual reports, as well as an approved end-user interface. Performance is subject to agency compliance reviews, and the vendor must provide a performance bond within 30 days of execution. Technical requirements mandate adherence to NIST and W3C standards, while security protocols require FIPS or NIST compliant encryption and annual information security audits. Respondents must submit comprehensive technical and cost proposals by December 1, 2026, including certifications regarding drug-free workplaces, non-collusion, and compliance with Florida statutory requirements such as E-Verify and restrictions on scrutinized companies. Evaluation is based on technical responses scored by at least three evaluators and a cost proposal, with a specific security rating determined by RiskRecon by Mastercard. All services must be performed within the United States, with a documented good faith effort to perform work within the State of Florida.

Agency for Health Care Administration

POSTED

DEADLINE

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)The National Institutes of Health is forecasting a Notice of Funding Opportunity to solicit applications for early to definitive clinical trials. This initiative seeks proposals testing a wide range of interventions, including drugs, devices, biologics, procedures, and behavioral or social interventions, provided they align with the research missions of the participating NIH Institutes, Centers, and Offices. The funding will utilize a bi-phasic, milestone-driven R61/R33 activity code with a maximum project period of seven years. The R61 phase focuses on planning activities, while the R33 phase supports the actual clinical trial. Although applications are not currently being accepted, this notice serves as an advance alert for investigators with expertise in trial design, implementation, and stakeholder engagement to begin developing collaborations and projects.

POSTED

DEADLINE

Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed)The National Institute on Aging intends to issue a single U24 cooperative agreement award to support the continued operation and expansion of the Exceptional Longevity Data Management and Coordinating Center. Serving as the central hub for human longevity translational research, the center integrates deeply phenotyped cohorts and multi-omics datasets to enable cross-cohort analyses and collaborative research. Key responsibilities include data harmonization, the implementation of common data standards, and the management of the ELITE Portal, which provides the research community with secure access to analytical tools and cloud-based computational workspaces. The upcoming funding opportunity will require the Coordinating Center to expand its capabilities in artificial intelligence, machine learning, and the integration of diverse datasets across different species. Future objectives include the development of curated target knowledgebases for therapeutic targets, the enhancement of portal interoperability according to FAIR data principles, and the strengthening of community engagement through specialized training and workshops. This notice serves as a forecast to allow potential applicants to establish collaborations before the official solicitation is released.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications for the NLM Grants for Scholarly Works in Biomedicine and Health program. This initiative provides funding for the creation of book-length manuscripts and other integrative scholarly works, such as critical reviews and analytical syntheses, designed to benefit U.S. health professionals, scientists, and public health practitioners. The primary goal is to organize and disseminate biomedical and health-related knowledge to improve research, education, and clinical practice. This opportunity is listed as a forecast with a posted date of September 24, 2026. It specifically prohibits the use of clinical trials. Interested parties can contact the NLM Extramural Programs office for further information regarding the application process and program requirements.

Book Publishers

POSTED

DEADLINE

Partnerships for Advancing Development of Diagnostics for Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking to establish partnerships between academic or small business investigators and industrial partners to advance the translational development of diagnostic tests for infectious diseases. This initiative focuses on moving diagnostics that have already demonstrated proof-of-concept through the commercialization process by aligning researchers with experienced industry partners to de-risk development and ensure products are fit for purpose. The program will be supported by a science advisory board and NIAID oversight, incorporating annual meetings and workshops to facilitate collaboration and knowledge exchange. This effort is authorized under the Public Health Service Act and federal regulations to ensure that promising diagnostic technologies are successfully translated into tools for treating and preventing infectious diseases.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting the LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) program. This initiative aims to bridge the gap between traditional clinical trial findings and real-world application by supporting collaborations on effectiveness trials, pragmatic trials, and hybrid effectiveness-implementation studies. The program focuses on the prevention and treatment of HIV, including associated coinfections and comorbidities, across all age groups and various points of care. The goal of the program is to advance cross-cutting research in epidemiology, implementation science, and clinical, behavioral, and social sciences. This effort aligns with the broader NIH mission to implement research advances in HIV/AIDS. The opportunity is authorized under the Public Health Service Act and relevant federal regulations, with administrative oversight provided by the Division of AIDS Epidemiology Branch.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Collaborative Centers in Children’s Environmental Health Research and Translation (P2C Clinical Trial Optional)The National Institutes of Health, under the Department of Health and Human Services, is seeking applications to establish a national network of Children's Environmental Health Research Translation Centers. These centers are designed to protect and improve children's health by developing scientific questions and public health interventions focused on translational research. A primary objective is to move evidence-informed biomedical findings into practical application for the wider community while mentoring a new generation of investigators in the field. Beyond research and translation, the program will function as a national resource to coordinate responses to emerging environmental exposures that impact children. The initiative emphasizes the creation of actionable strategies to prevent harm and ensure a healthy future for children through collaborative efforts within the environmental health community.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

The Role of the Innate Immune System in the Pathogenesis of Type 1 DiabetesThe National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting a grant opportunity to investigate the role of the innate immune system in the initiation of Type 1 Diabetes. Funded by the Special Statutory Funding Program for Type 1 Diabetes Research, this initiative seeks to identify genetic and environmental causes of the disease by examining how innate immune components interact with beta cells and pancreatic tissues. The program emphasizes the use of new approach methodologies to determine the timing and impact of environmental triggers that activate these immune pathways. The primary objective is to improve the early identification of high-risk individuals and develop future prevention and therapeutic strategies. This effort is conducted under the authority of the Public Health Service Act and relevant federal regulations. Interested parties can contact the RISP-T1D point of contact for further information regarding this forecast.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)The National Institute of Neurological Disorders and Stroke (NINDS) is seeking to support scientific research using data from intermediate-size patient population expanded access protocols for Amyotrophic Lateral Sclerosis (ALS). To be eligible, protocols must provide access to an investigational drug or biological product for individuals with ALS and generate data that supports research into the prevention, diagnosis, mitigation, treatment, or cure of the disease. Research goals may include analyzing the effects of products on biomarkers, target engagement, safety and outcome information such as survival and hospitalization, or general patient experience data. This opportunity is currently listed as a forecast by the National Institutes of Health under the Department of Health and Human Services, and applications are not being solicited at this time. The notice serves as a preliminary announcement to allow potential applicants sufficient time to develop responsive projects. Interested parties can contact the ALS Program for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Research to Improve Rigor, Replicability, and Reproducibility in Biomedical and Behavioral SciencesThe National Institute of Neurological Disorders and Stroke, in collaboration with other NIH entities, is forecasting support for research projects aimed at enhancing biomedical and behavioral rigor, replicability, and reproducibility. Key areas of interest include assessing the scientific impact of these improvements, creating frameworks for selecting high-value replication studies, and measuring the robustness and generalizability of research findings to drive scientific innovation. This notice serves as a forecast to allow potential applicants to establish collaborations and develop responsive projects, as formal applications are not currently being solicited. Interested parties can contact the NINDS Office of Research Quality for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)The National Institutes of Health, through the National Institute of Mental Health, is issuing a forecast for a Notice of Funding Opportunity titled Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs). This initiative aims to establish a research network to evaluate the clinical effectiveness, safety, and durability of rapid-acting treatments such as ketamine, esketamine, and psilocybin for individuals with serious mental illnesses. The primary objective is to generate actionable real-world evidence to determine how these interventions can be safely and sustainably integrated into routine clinical practice across diverse patient populations and healthcare settings. By addressing current gaps in knowledge regarding implementation and long-term benefits, the project seeks to inform future healthcare delivery strategies for emerging psychotropic treatments.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Emerging Global Leader Award (K43)The Emerging Global Leader Award (K43), issued by the National Institutes of Health under the Department of Health and Human Services, provides salary and research support to junior faculty and research scientists based at academic or research institutions in Low- and Middle-Income Countries. The program focuses on biomedical, behavioral, and clinical research that leverages unique opportunities in these regions to create generalizable knowledge benefiting both U.S. and international populations. Recipients must engage in intensive mentored research and career development guided by senior researchers from both the U.S. and their respective home countries. By leveraging existing NIH research investments, the initiative aims to develop global research leaders who can mentor future investigators and strengthen international research networks.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS